Evidence map›Paper›PMID 34770107›Full record

ArticleInternational journal of environmental research and public health2021

Development of a Model Care Pathway for Myasthenia Gravis.

Anil Babu Payedimarri, Matteo Ratti, Riccardo Rescinito, Alessandra Vasile, Deborah Seys, Hervé Dumas, Kris Vanhaecht, Massimiliano Panella

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Anil Babu PayedimarriDepartment of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy.ORCID 0000-0003-4298-1305
Matteo RattiDepartment of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy.ORCID 0000-0002-9273-9114
Riccardo RescinitoDepartment of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy.ORCID 0000-0003-0117-3432
Alessandra VasileDepartment of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy.
Deborah SeysEuropean Pathway Association, 3000 Leuven, Belgium.ORCID 0000-0003-4966-3879
Hervé DumasUCB Pharma, 1630 Bulle, Switzerland.
Kris VanhaechtEuropean Pathway Association, 3000 Leuven, Belgium.
Massimiliano PanellaDepartment of Translational Medicine (DIMET), Università del Piemonte Orientale, 28100 Novara, Italy.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITEuropean Pathway Association · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG. The development of the model CP, key interventions, and process indicators is based on the literature review and 85 international MG experts were involved in their evaluation, expressing a judgment of relevance through the Delphi study. 60 activities are included in the model CP and evaluated by the MG experts were valid and feasible. The 60 activities were then translated into 14 key interventions and 24 process indicators. We believe that the developed model CP will help for MG patients to have a timely diagnosis and high-quality, accessible, and cost-effective treatments and care. We also believe that the development of model CPs for other rare diseases is feasible and could aid in the integration of evidence-based knowledge into clinical practice.

Indexed as

Myasthenia GravisHumanscare pathwayclinical pathwaycore activitiescritical pathwayintegrated care pathwaykey interventionsmodel pathwaymyasthenia gravisprocess flowquality indicators

Identifiers

PMID34770107
PMCPMC8582978
OpenAlexW3213862320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.